Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients in relapse or considered at high risk for relapse or refractory CD-20-positive B-cell NHL or CLL. Patients considered for high risk of relapse are patients who do not achieve complete response (CR) with frontline chemotherapy, CLL is Richter's and CLL with high risk chromosomal abnormalities.~2. Measurable disease.~3. Age 18-70 years, expected survival \>/= 3 months, performance status 0 to 2.~4. Availability of a matched related donor.~5. \</+ 50% bone marrow involvement.~6. CLL with \</+ 10,000 circulating lymphocytes.~7. Availability of a matched related or unrelated donor.~Exclusion Criteria:~1. Prior myeloablative therapies or radioimmunotherapy.~2. Prior external beam radiation therapy to \>25% of active bone marrow.~3. Prior therapy with 90Y Zevalin or Campath.~4. CNS lymphoma, HIV, HTLV-1 positivity, some creatinine \>1.6 mg/dl or serum bilirubin \>1.5 mg/dl.~5. Pregnancy or lactation.~6. Symptomatic pulmonary or cardiac disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 90Y Zevalin in ASCT (Type: EXPERIMENTAL): Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).